Just from selling other RX, I believe all AE's an

Just from selling other RX, I believe all AE's and SAE's have to be reported during a trial no matter if they are related to the drug or not. Once the trial is unblinded the number of patients experiencing each event is noted and given a percentage. As an example the results will show something like ~20% or more mortality in patients in the Placebo or control group vs 0% mortality in the Leronlimab group. Cytodyn will take the most common/frequent AE and SAE's and put them in a table in the product insert and will list all others in the "warnings" section. This information is how a rep sells their product. I would present the results kinda like this, " Dr. as you can see from the clinical trial data, 2 patients died in the Leronlimab group compared to 18 in the control group" Dr, also keep in mind, many of the patients in both groups had other life threatening health conditions including severe end organ damage" Would you agree that the Leronlimab group had significantly better outcomes than control? Just my opinion